B cell lymphoma and the microbiome

A key challenge in mining the microbiome for therapeutic strategies has been to characterize the functional role of specific bacterial populations in the context of a disease. Now, University of California researchers have shown the gut microbiome is a key contributor to lymphoma risk and identified specific alterations to microbiome composition that could potentially attenuate this risk.¹

The UC researchers are sifting through a set of bacterial species to identify those that could be used as probiotics or targeted to alter disease phenotypes, and have founded Microbio Pharma Inc. to develop and commercialize resulting products...